20 percent more patients were treated with proton therapy in 2019
An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB
Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt
For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany.
500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.
To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.
Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB.
- Nanoislands on silicon with switchable topological texturesNanostructures with specific electromagnetic patterns promise applications in nanoelectronics and future information technologies. However, it is very challenging to control those patterns. Now, a team at HZB examined a specific class of nanoislands on silicon with interesting chiral, swirling polar textures, which can be stabilised and even reversibly switched by an external electric field.
- Lithium-sulphur pouch cells investigated at BESSY IIA team from HZB and the Fraunhofer Institute for Material and Beam Technology (IWS) in Dresden has gained new insights into lithium-sulphur pouch cells at the BAMline of BESSY II. Supplemented by analyses in the HZB imaging laboratory and further measurements, a new picture emerges of processes that limit the performance and lifespan of this industrially relevant battery type. The study has been published in the prestigious journal Advanced Energy Materials.
- Largest magnetic anisotropy of a molecule measured at BESSY IIAt the Berlin synchrotron radiation source BESSY II, the largest magnetic anisotropy of a single molecule ever measured experimentally has been determined. The larger this anisotropy is, the better a molecule is suited as a molecular nanomagnet. Such nanomagnets have a wide range of potential applications, for example, in energy-efficient data storage. Researchers from the Max Planck Institute for Kohlenforschung (MPI KOFO), the Joint Lab EPR4Energy of the Max Planck Institute for Chemical Energy Conversion (MPI CEC) and the Helmholtz-Zentrum Berlin were involved in the study.